Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis | Zendy

Ildiko Lingvay | Zendy; Matthew Capehorn | Zendy; AndreiMircea Catarig | Zendy; Pierre Johansen | Zendy; Jack Lawson | Zendy; Anna Sandberg | Zendy; R. H. Shaw | Zendy; Abby Paine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

Author(s) -

Ildiko Lingvay,

Matthew Capehorn,

AndreiMircea Catarig,

Pierre Johansen,

Jack Lawson,

Anna Sandberg,

R. H. Shaw,

Abby Paine

Publication year - 2020

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/clinem/dgaa577

Subject(s) - empagliflozin , semaglutide , medicine , type 2 diabetes , metformin , confidence interval , clinical endpoint , diabetes mellitus , randomized controlled trial , urology , pharmacology , endocrinology , insulin , liraglutide

No head-to-head trials have directly compared once-weekly (OW) semaglutide, a human glucagon-like peptide-1 analog, with empagliflozin, a sodium-glucose co-transporter-2 inhibitor, in type 2 diabetes (T2D).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research